GC Cell license out T-cell lymphoma treatment to US affiliate

GC Cell said that it has signed a technology export contract for AB-205, a T-cell lymphoma treatment, with Artiva Biotherapeutics, its U.S. affiliate.According to GC Cell, AB-205 is an allogeneic cord blood-derived NK cell therapy drug equipped with a Chimeric Antigen Receptor (CAR) that targets CD5

Leave a Comment

Your email address will not be published.

Generated by Feedzy